anti-GPC3 AD2C / Acepodia - LARVOL DELTA

Development of dual-payload anti-GPC3 antibody-drug conjugate by dual-payload antibody conjugation (AD2C) platform for hepatocellular carcinoma treatment (AACR 2025) - "The HCC xenograft study further demonstrated that the anti-GPC3 AD2C completely suppressed tumor growth at doses of up to 10 mg/kg, with no significant body weight change observed. In conclusion, the dual-payload ADC produced by AD2C platform offers a potential strategy to overcome tumor heterogeneity and drug resistance while maintaining an ideal safety profile, supporting its potential clinical application in HCC treatment."

Hepatocellular Cancer • Oncology • Solid Tumor • GPC3

Acepodia Presents Preclinical Data on Antibody-Dual-Drugs Conjugation (AD2C) technology at AACR Annual Meeting 2025 (PRNewswire) - "The poster presentation, titled 'Development of dual-payload anti-GPC3 antibody-drug conjugate by dual-payload antibody conjugation (AD2C) platform for hepatocellular carcinoma treatment,' showcases the company's next-generation ADC generated using Acepodia's AD2C platform. This platform allows for the conjugation of two distinct payloads to a single antibody without the need of antibody engineering or enzymatic conjugation. AD2C, carrying payloads with different mechanisms of action, offer enhanced therapeutic potency by targeting diverse cell populations in heterogeneous tumors or overcoming resistance to single-payload therapy."

Preclinical • Hepatocellular Cancer